UNSPSC 51281907: Rufocromomycin or streptonigrin

This classification denotes an antineoplastic antibiotic with the molecular structure C25H22N4O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 261Q3JB310 chemically known as 2-pyridinecarboxylic acid, 5-amino-6-(7-amino-5,8-dihydro-6-methoxy-5,8-dioxo-2-quinolinyl)-4-(2-hydroxy-3,4-dimethoxyphenyl)-3-methyl- but generally known as rufocromomycin, which bears US NIH Compound Identifier 5323583.

UNSPSC 51281907 Rufocromomycin or streptonigrin is a Commodity code covering pharmaceutical active ingredients used in clinical and research applications. State and local health agencies and benefit program administrators solicit these materials primarily through pharmacy benefit and pharmaceutical procurement channels, though direct commodity purchasing at this specificity level is uncommon in state and local contracting. The single recent opportunity in the dataset—the Texas Health and Human Services Commission's Request for Information on Direct-to-Manufacturer Prescriptions (RFI HHS0017013, posted April 3, 2026)—does not solicit the commodity itself but rather vendor capabilities for implementing direct pharmacy contracting models between state programs and manufacturers outside traditional pharmacy benefit manager and wholesaler channels. This RFI targets vendors capable of direct contracting with self-insured employer plans and state agencies on negotiated net pricing and outcomes-based models, suggesting the state is exploring supply chain restructuring rather than procuring specific pharmaceutical compounds.

The code shows minimal recent state and local activity specific to this active ingredient. The Texas HHS RFI addresses pharmacy benefit program architecture and vendor partnerships rather than procurement of rufocromomycin or streptonigrin as discrete products. State and local governments typically acquire pharmaceuticals through established GPO contracts, state health plan formularies, and wholesaler relationships rather than direct commodity purchasing at the active-ingredient level. Without additional recent opportunities demonstrating direct solicitation of this substance by state or local health systems, school districts, or corrections departments, the code appears inactive in state and local procurement markets at present.